Boston Scientific Corp (BSX) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Boston Scientific Corp (BSX)

42.68

-0.80 (1.84%)

as of Jun 30, 2026, 8:00:00 pm Market Open.

101 watching

Investor Insights

Jun 30, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Boston Scientific Corp (BSX-N) has been experiencing challenges lately, with a notable decline in stock performance since 2025, breaking critical support levels and exhibiting technical weaknesses as it currently trades below its 200-day moving average. Organic growth has been subpar, as the company recently cut guidance from projected rates, which has contributed to a lack of investor confidence. While the firm is recognized as a leading player in the medical device sector, specifically in non-invasive heart instrumentation, competition has intensified, leading to market share losses against bigger players like Medtronic and Abbott. Despite a strong long-term outlook fueled by aging demographics and increasing demand for cardiovascular procedures, analysts are cautious, recommending a wait-and-see approach as the current valuation appears too high. Overall, Boston Scientific remains a quality organization within its sector, but near-term uncertainties warrant skepticism.

Consensus

Sell

Valuation

Overvalued

Similar

MDT

DON'T BUY

Had an earnings disappointment. FMV trend is sharply down. When factoring in analysts forecasts, the FMV is about $12.30.

BUY ON WEAKNESS

Will have to go to $20.50 before it has a bounce. Has a model price of $31.95 which is a 37/38% differential.

BUY

In a lawsuit with Johnson and Johnson (JNJ-N), so a lot depends on who wins the case. Their product works better than JNJ and he continues to like it.

BUY

Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N).

WEAK BUY

It's close to a buy. Model price is $32.09 which is a 5% differential.

TOP PICK

"We really like Boston [Scientific]" Thinks they have a better product then the competitor. Had a series of recalls, but have been able to gain back the marketshare. But the stock didn't recover as well. So is now undervalued.

DON'T BUY

Long term chart shows that it made a base, had a fantastic rise to $45 in 2002/2003, very little top formation and now we are in a downtrend. Stock has now fallen below its 200 day moving average.

BUY

A good company. Their coated stents is a terrific product. Up against Johnson & Johnson in the stent business, but they are holding their own. A good buy at this price.

WEAK BUY

Stock has dropped because of the recall of their stent. Price is reasonably attractive.

TOP PICK

A company that focuses on earnings. A tremendous new product that should give a nice boost to their income.

DON'T BUY

Its drug coated stent is driving the price up, but other competitors are lurking on the horizon. Not cheap.

TOP PICK

Likes this sector. Strong and persistant growth. Revenue and earnings growth has been very persistant. Good products. Buy on pull backs.

Showing 61 to 72 of 72 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Murray

The Murray Wealth Group

Joe Terranova

Virtus Investment Partners

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)